Trading leveraged product involves significant risk of loss. 24.46% of retail investor accounts generate profits when trading leveraged products with this provider

MERCK & CO. Stock (MRK.re) Price Chart, Analysis, and Forecast

View the real-time MERCK & CO. (MRK.re) stock quote and decide if you want to buy and when to sell. Find predictions, financials, the latest news and other information to help you with your stock investing.

$145.98
0.25%
Followers
34
Annual change
69.39%
Buy
146.02
0.04
Sell
145.98
Daily price range:
Low
145.58
High
147.71
Trade MRK

All investing involves risk

MRK live price

Live Chart

Past performance is not a reliable indicator of future results.

Is MERCK & CO. a good stock to buy?

The quantitative stock rating system created by TipRanks shows that MERCK & CO. price is overperforming. Its Smart Score¹ of 9 indicates MERCK & CO. is one of the best stocks to buy or watch now in أكتوبر.

9

Smart Score

Why is MERCK & CO. stock price going up?

MERCK & CO.

Bulls say

  • MRNA oncology platform

    Positive Phase 3 results for an individualized mRNA cancer vaccine would validate a novel oncology platform and diversify the company's long-term oncology growth prospects, analyst notes.

  • TROP2 antibody-drug conjugate

    Full results from the TROP2-directed antibody-drug conjugate program could clarify competitive positioning across multiple solid tumors and support development of a major oncology growth franchise, analyst says.

  • Inflammation franchise potential

    Strong efficacy and a clean safety profile for tulisokibart in hidradenitis suppurativa would validate TL1A inhibition and position the drug as a potential foundational growth driver for the inflammation portfolio, analyst observes.

  • Individualized vaccine execution risk

    Safety concerns, manufacturing complexity and uncertain regulatory pathways for the individualized vaccine could reduce its commercial prospects if any of these areas encounter setbacks, analyst warns.

  • Loss of exclusivity risk

    Loss of exclusivity for the company's leading PD-1 therapy remains a significant overhang that could pressure revenue and overall company outlook, analyst states.

  • Ophthalmology safety concerns

    Higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and treatment discontinuations with remigromig raise adoption and reimbursement concerns until comprehensive safety datasets are reviewed, analyst cautions.

Why is MERCK & CO. stock price going down?

MERCK & CO.

Bears say

    No bearish insights available yet.

What is happening with
MERCK & CO. stock price today?

  • The price of MERCK & CO. today, as of October 16, 2026, was $145.98. That's up 0.25% from the previous session's MERCK & CO. closing price.

  • The MERCK & CO. price is rising this week. Compared to last week, the rate of MERCK & CO. is up 0.80%, and it's down -0.10% from one month ago.

  • The 52-week MERCK & CO. price high is $156.89, while the 52-week MERCK & CO. price low is $82.02.

  • Year to date, MERCK & CO. price is up 71.50% from the beginning of the year and has had a return of 71.50% in the last 12 months.

What is the sentiment of MERCK & CO. stock in أكتوبر 2026?

The sentiment score², indicating how the crowd feels about MERCK & CO. stock is NEGATIVE. The sentiment signal³ observed at the start of the market session, offering insights into whether MERCK & CO. stock price today is likely to increase, decrease, or remain steady, is BEARISH.

News Sentiment
Very Bullish
Very Bullish
Bullish: 83%Bearish: 17%
Blogger Opinion
Bullish
Bullish
Bullish: 75%Bearish: 25%
Investors Sentiment
Negative
Negative
Past 7d: 0%Past 30d: -2%

Table with the sentiment of MERCK & CO. stock in أكتوبر 2026

MERCK & CO. stock analysis

Based on analysts giving ratings to MERCK & CO. stock, the consensus⁴ is BUY. Hedge funds activity⁵ increased in the last quarter, while Insider activity⁶ trend is bearish (sold MERCK & CO. shares)

MERCK & CO. Technical Analysis

Trending upPositive
SMA
Trending up0.79
Momentum

Simple moving average: 20/200 days

Momentum: 12 month change

MERCK & CO. Insider Activity

Trending downsold shares
Trend

Net -30M shares last quarter

MERCK & CO. Fundamentals

Trending up+7.0%
Return on equity
Trending up+10.0%
Asset Growth

Return on equity: last 12 months

Asset growth: 12 month change

Discover key MERCK & CO. stock trends with NAGA Insights

What am I Missing?

  • Make informed decisions based on real-time data, expert analysis, and powerful research tools from TipRanks.

  • Access advanced MERCK & CO. charting, technical analysis, and live market data from TradingView.

  • Get AI-powered MERCK & CO. trade signals, in-depth market analysis, and technical strategy insights from Trading Central.

Sign up

All investing involves risk

Best Stocks Discover

MERCK & CO. stock outlook 2026

Analysts forecast MERCK & CO. stock price will rise in the next 12 months. Based on 21 Wall Street analysts offering MERCK & CO. price predictions in the last 3 months, the average price target is $160.00.

The highest MERCK & CO. stock forecast is $180.00, while the lowest is $105.00. The average MERCK & CO. price target represents a 9.63% change from the actual price of $145.98.

MERCK & CO. stock price prediction⁷

  • Highest price target$180.00
  • Average price target$160.00
  • Lowest price target$105.00

MERCK & CO. stock forecast⁸

  • Buy71.43%
  • Hold28.57%
  • Sell0.00%

Overview of stock forecast and price predictions 2026. Analyst price targets and consensus are estimates only and do not constitute guarantees of future outcomes.

Investing in MERCK & CO. stock

There are two ways to invest in MERCK & CO. stock: trading MERCK & CO. stock through derivatives like CFDs or buying shares of MERCK & CO. stock outright. With NAGA.com, you can do both and more.


Buy MERCK & CO. shares of stock if you want to hold them for a long time. You commit the full value of the MERCK & CO. shares outright and profit only if they increase in price.


Trade MERCK & CO. if you want more flexibility — say you want to speculate on its price movements in both directions. With CFDs, you can open a buy position (go long) if you think MERCK & CO. stock’s price will rise, or you can open a sell position (go short) if you believe the MERCK & CO. stock’s price will fall.


You won’t need to commit to the full value of the position. But bear in mind that leverage can increase both your profits and losses.

How to invest

How to trade MERCK & CO. with CFDs?

  • If you want to speculate on MERCK & CO. price, search for MERCK & CO. CFD. Then click on the "MERCK & CO." symbol to view the chart and other insights before placing your trade. Also, review "MERCK & CO." contract specification to be aware of all the MERCK & CO. CFD trading conditions.

How to buy MERCK & CO. stock?

  • If you want to buy MERCK & CO. shares outright to hold them for a long time, search for MERCK & CO. stock with ownership (Real Stocks). Then click on the "MERCK & CO." symbol to view the chart and other insights before placing your trade. Also, review "MERCK & CO." contract specification to be aware of all the MERCK & CO. stock buying conditions.

trading conditions:

Platform
MT5
Ticker#MRK.re
Volume step
Lot value
Minimum trade size
Maximum trade size
Commission0.00%
Monthly price change (%)0.12%
Annual price change (%)69.39%
Digits
Tick value0.01
Trading Hours & Fees
Get Started

All investing involves risk

MERCK & CO. company presentation

MRK

Merck & Co.

Real Stocks

0.25%

$146.02
$145.98

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Latest MERCK & CO. stock news

Discover the latest news that can influence MERCK & CO.’s earnings sentiment and MERCK & CO. forecast and price predictions.

Neutral
If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys
17/10/2026/05:04
Read more
Neutral
RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)
16/10/2026/21:46
Read more
Neutral
Stock futures are little changed as S&P 500 heads for losing week: Live updates
16/10/2026/10:07
Read more

FAQs about MERCK & CO. trading

The price of MERCK & CO. stock today, as of October 16, 2026, was 145.98. That's up 0.25% from the previous session's MERCK & CO. closing price.

IMPORTANT NOTICE: The content presented in the instrument page is only for informational, educational and support purposes. The material presented, including analyses, sentiment, consensus, prices, opinions or other content, is not an investment recommendation or information that recommends or suggests an investment strategy, nor is it included in the scope of investment advice. NAGA will not accept liability for any loss or damage, including but not limited to any loss of profits, that may arise directly or indirectly from the use of or reliance on the information contained in this page. NAGA is not responsible for the actions or omissions of the client, especially for the acquisition or disposal of financial instruments, made based on the information contained in this page. Past performance is not necessarily indicative of future results, and anyone acting on this information does so at their own risk. ¹ ⁵ ⁶ The Smart Score is a proprietary quantitative stock scoring system created by TipRanks. It assigns stocks a score from one to ten, based on 8 market key factors. The lowest score is 1, and the highest is 10. Stocks with a score of 8, 9, or 10 are considered Outperform, and with a score of 1, 2, or 3 are considered Underperform. The score is data-driven and does not involve any human intervention. The contributing market factors are Wall Street analyst ratings, Corporate insider transactions, Financial blogger opinions, Individual investor sentiment, Hedge fund manager activity, News sentiment, Technicals and Fundamentals. This information is provided for indicative purposes only and should not be interpreted as investment advice or a recommendation to trade. ⁴ ⁷ ⁸ TipRanks’ consensus ratings provide an aggregated view of expectations and consensus on a particular stock from a wide range of global analyst opinions. They’re then condensed into a single indicator, which can help you make investment decisions based on expert analysis. TipRanks’ 12-month forecast is a consensus price target derived from Wall Street analysts’ projections made over the past three months. It forecasts the potential high, low, and average share price for a stock one year from now, along with the average expected upside or downside percentage. ² ³ The sentiment signal and sentiment score are provided by Trading Central. Sentiment insights and market views are based on available data and do not guarantee future performance.

Need Help? Visit our Help Section
Download NAGA Trader

Copyright © 2026 – All rights reserved.

NAGA is a trademark of The NAGA Group AG, a German based FinTech company publicly listed on the Frankfurt Stock Exchange | WKN: A41YCM | ISIN: DE000A41YCM0.

The website is operated by KEY WAY MARKETS LTD a Company limited by shares that is formed and registered under the Laws of the Abu Dhabi Global Market (“ADGM”) under license number 000003041, authorized and regulated by the Financial Services Regulatory Authority (“FSRA”) with Financial Services Permission Number 190005, having its registered offices at Office 2, 21st Floor, Al Sila Tower, ADGM Square, Al Maryah Island, Abu Dhabi, United Arab Emirates (“the Company”).

The Company is authorized to provide financial products and services to Retail Clients and to persons who meet the qualifying criteria of a Professional Client as defined in the ADGM Conduct of Business Module. Other group entities: NAGA Markets Europe Ltd, authorized and regulated by the Cyprus Securities and Exchange Commission ("CySEC") under license No. 204/13 with registered address at Agias Zonis 11, Limassol, 3027, Cyprus.

RISK WARNING: Trading leveraged products (CFDs) and real shares involves significant risk, including the potential loss of your initial investment, and may not be suitable for all investors. Before trading or investing, you are strongly advised to read and ensure you understand the relevant Risk Disclosure and warnings included in the Company's legal documents section. There is a substantial risk that you may lose all of your initial investment when trading or investing. We recommend that you carefully consider whether trading leveraged products or investing in shares is appropriate for you in light of your personal circumstances, and ensure you fully understand all associated risks before proceeding. 24.46% of retail investor accounts generate profits when trading leveraged products with this provider. Trading with NAGA Trader by following and/or copying or replicating the trades of other traders involves high levels of risks, even when following and/or copying or replicating the top-performing traders. Such risks include the risk that you may be following/copying the trading decisions of possibly inexperienced/unprofessional traders, or traders whose ultimate purpose or intention, or financial status may differ from yours. Before making an investment decision, you should rely on your own assessment of the person making the trading decisions and the terms of all the legal documentation.

Disclaimer: The content on this page is for informational purposes only and is not intended as a recommendation or advice. Any references to past performance, emulated performance, or forecasts in the Company’s advertisements are not reliable indicators of future results. Customers are solely responsible for their own business decisions or investments.